Publication Type:Academic Journal

Source(s):Medicina (Kaunas, Lithuania) [Medicina (Kaunas)] 2022 Jul 03; Vol. 58 (7). Date of Electronic Publication: 2022 Jul 03.

Abstract:Background and Objectives: Hemodialysis patients (HD) and kidney transplant recipients (KTRs) have been heavily impacted by COVID-19, showing increased risk of infection, worse clinical outcomes, and higher mortality rates than the general population. ...

Publication Type:Academic Journal

Source(s):The Journal of allergy and clinical immunology [J Allergy Clin Immunol] 2022 Jun; Vol. 149 (6), pp. 1949-1957. Date of Electronic Publication: 2022 Apr 11.

Abstract:Background: Patients with inborn errors of immunity (IEI) are at increased risk of severe coronavirus disease-2019 (COVID-19). Effective vaccination against COVID-19 is therefore of great importance in this group, but little is known about the immunoge...

Publication Type:Academic Journal

Source(s):American journal of clinical pathology [Am J Clin Pathol] 2022 Aug 04; Vol. 158 (2), pp. 167-172.

Abstract:Objectives: Despite the clear benefits of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in mitigating the impact of the coronavirus disease 2019 pandemic, there are emerging reports of postvaccination myocarditis, the majorit...

Publication Type:Academic Journal

Source(s):Neurology(R) neuroimmunology & neuroinflammation [Neurol Neuroimmunol Neuroinflamm] 2022 Jun 21; Vol. 9 (4). Date of Electronic Publication: 2022 Jun 21 (Print Publication: 2022).

Abstract:Background and Objectives: Evidence regarding the safety and efficacy of messenger RNA (mRNA) vaccines in patients with myasthenia gravis (MG) after immunosuppressive therapies is scarce. Our aim is to determine whether the mRNA-1273 vaccine is safe an...

Publication Type:Academic Journal

Source(s):Frontiers in immunology [Front Immunol] 2022 Jun 16; Vol. 13, pp. 864718. Date of Electronic Publication: 2022 Jun 16 (Print Publication: 2022).

Abstract:mRNA based vaccines against COVID-19 have proven most successful at keeping SARS-CoV-2 pandemic at bay in many countries. Recently, there is an increased interest in heterologous prime-boost vaccination strategies for COVID-19 to maintain antibody resp...

Publication Type:Academic Journal

Source(s):Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology [J Clin Virol] 2022 Jun; Vol. 150-151, pp. 105156. Date of Electronic Publication: 2022 Apr 06.

Abstract:Background: In Taiwan, the vaccination program started in March 2021, with ChAdOx1-S being the first available WHO-approved COVID-19 vaccine, followed by Moderna vaccine. This study aimed to investigate the immunogenicity and safety of homologous and h...

Publication Type:Academic Journal

Source(s):The journal of allergy and clinical immunology. In practice [J Allergy Clin Immunol Pract] 2022 Aug; Vol. 10 (8), pp. 2166-2168.e1. Date of Electronic Publication: 2022 May 03.

Publication Type:Academic Journal

Source(s):American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons [Am J Transplant] 2022 Aug; Vol. 22 (8), pp. 2089-2093. Date of Electronic Publication: 2022 Mar 21.

Abstract:The SARS-CoV-2 virus Omicron variant has now supplanted wild-type virus as the dominant circulating strain globally. Three doses of mRNA COVID-19 vaccine are recommended for transplant recipients as their primary vaccine series. However, the immunogeni...

Publication Type:Report

Source(s):Transplantation [Transplantation] 2022 Jul 01; Vol. 106 (7), pp. e341-e342. Date of Electronic Publication: 2022 Mar 23.

Publication Type:Academic Journal

Source(s):Nature communications [Nat Commun] 2022 Jun 02; Vol. 13 (1), pp. 3082. Date of Electronic Publication: 2022 Jun 02.

Abstract:SARS-CoV-2 Omicron BA.1 and BA.2 subvariants are genetically divergent. We conducted a matched, test-negative, case-control study to estimate duration of protection of the second and third/booster doses of mRNA COVID-19 vaccines against BA.1 and BA.2 i...